How many drugs treat Pulmonary hypertension?

Drug Landscape tracks 6 marketed treatments for Pulmonary hypertension (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/pulmonary-hypertension.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pulmonary hypertension — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pulmonary hypertension (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pulmonary hypertension, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Tracleer	BOSENTAN	AstraZeneca	Endothelin Receptor Antagonist	Endothelin-1 receptor	2001-01-01
Inomax	NITRIC OXIDE	Vero Biotech Inc	Standardized Chemical Allergen [EPC]	Soluble guanylate cyclase	1999-01-01
Flolan	EPOPROSTENOL	AstraZeneca	Prostacycline Vasodilator [EPC]	Prostacyclin receptor	1995-01-01
Cialis	tadalafil	Eli Lilly	Phosphodiesterase 5 Inhibitor [EPC]	Nuclear receptor subfamily 2 group E member 1, Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Potassium voltage-gated channel subfamily H member 2
prostacyclin	prostacyclin	United Therapeutics		P2Y purinoceptor 12, Prostacyclin receptor, Prostaglandin E2 receptor EP1 subtype
Cialis	Cialis	Ottawa Hospital Research Institute		Nuclear receptor subfamily 2 group E member 1, Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Potassium voltage-gated channel subfamily H member 2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

AstraZeneca · 2 drugs in Pulmonary hypertension
Eli Lilly · 1 drug in Pulmonary hypertension
Ottawa Hospital Research Institute · 1 drug in Pulmonary hypertension
United Therapeutics · 1 drug in Pulmonary hypertension
Vero Biotech Inc · 1 drug in Pulmonary hypertension

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pulmonary hypertension:

Cite this brief

Drug Landscape (2026). Pulmonary hypertension — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pulmonary-hypertension. Accessed 2026-06-10.

Pulmonary hypertension full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing